Lv31
354 积分 2023-11-16 加入
Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
23天前
已完结
Overall survival assessment in cancer drug trials: a luxury or a necessity?
28天前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
1个月前
已完结
Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial
1个月前
已完结
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN study
2个月前
已完结
First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study
2个月前
已完结
A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer
2个月前
已完结
Prophylactic Versus Therapeutic Sucralfate in Patients at High Risk for Radiation Esophagitis: Randomized Controlled Trial
2个月前
已关闭
多原发肺癌临床诊治进展
3个月前
已完结
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
3个月前
已完结